Lonza’s innovative continuous flow technology and mini-monoplant approach are transforming early-phase drug development. How ...

The study found that average out-of-pocket costs for drugs for MS increased by 217% over a nine-year period. Costs have dropped for medications where generic versions have been introduced.

In the United States, out-of-pocket (OOP) costs of brand-name medications for ... medications and biosimilars where available ...

The path from a scientist’s initial idea to a new medicine that can save lives is a complex and often lengthy process. It ...

Artificial intelligence (AI) can accelerate drug development, reduce costs, and improve treatment efficacy, but faces challenges like data quality and regulatory hurdles. Over 900 FDA-approved AI ...

Among the top 20 biopharmaceutical companies, the average research and development (R&D) cost to advance a new drug program all ... their programs from discovery phase to initiating clinical ...

The Alzheimer’s Association hailed the development ... A six-month course would cost $12,522 while the drug would cost $48,696 for patients who need to stay on it for 18 months.

Through a new partnership announced last week, HealthJoy and Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) hope to expand access to affordable drugs for employees. Chicago-based HealthJoy is ...

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal. The Danish pharma bought the nonsteroidal ...

Longboard Pharmaceuticals, Inc. ( (LBPH) ) has released its Q3 earnings. Here is a breakdown of the information Longboard Pharmaceuticals, Inc.

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, especially for MS ...